Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of inflammatory and infectious diseases.
Business. Marinomed Biotech AG is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in Austria and primarily listed on the Wiener Börse under the ticker MARI.VI. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Marinomed Biotech AG is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in Austria and primarily listed on the Wiener Börse under the ticker MARI.VI. Specific details regarding operating segments and geographic revenue mix are not available.
Marinomed Biotech AG has a negative equity position of EUR -11.84 million and a debt-to-equity ratio of -1.84, indicating a leveraged capital structure with liabilities exceeding assets. The company's liquidity position is characterized by a current ratio of 1.87, supported by EUR 1.86 million in cash and equivalents, but this is insufficient to cover the EUR 23.99 million in total liabilities. The negative operating cash flow of EUR -0.94 million and free cash flow of EUR -1.97 million further highlight the company's cash flow challenges.
The company's profitability is weak, with a net loss of EUR -2.13 million and an operating loss of EUR -1.88 million in the latest reporting period. Return on assets is negative at -17.54%, and return on equity is 17.99%, which is unusually high given the negative equity position and may reflect accounting distortions. These metrics fall significantly below the industry median for profitability and returns, indicating underperformance relative to peers.
Marinomed Biotech AG's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. The company's revenue of EUR 737.50 million is derived from its core biopharmaceutical operations, with no material contributions from other business lines or regions.
The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the latest period. Analysts have assigned a mean price target of EUR 50.82, with a strong buy recommendation, but this is based on a single analyst's opinion. The absence of a clear growth narrative and the company's financial underperformance suggest a high degree of uncertainty in its future performance.
The company faces medium liquidity risk due to its negative net cash position and high debt load. The risk assessment indicates low dilution potential, but the company's negative equity and high leverage increase the risk of further capital raising through equity issuance. The absence of a detailed risk management strategy in the latest filings raises concerns about the company's ability to manage financial distress.
Recent events include the publication of the latest financial results, which show continued losses and a deteriorating balance sheet. No material regulatory or legal developments were disclosed in the latest filings, but the company's exposure to the pharmaceutical industry's regulatory environment remains a key risk factor.
- Marinomed Biotech AG has a negative equity position and a high debt-to-equity ratio, indicating a leveraged capital structure.
- The company's profitability is weak, with a net loss and negative return on assets, underperforming industry medians.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Analysts have assigned a strong buy recommendation, but the company's financial underperformance and lack of growth suggest high uncertainty.
- The company faces medium liquidity risk and potential dilution from further capital raising.
Bull / Bear case
Generated · model-assistedAnalysts project 408% upside to a target price of EUR 50.82, rating the stock a strong buy.
Revenue is forecast to surge 62% year-over-year to EUR 7.7 million in fiscal 2026.
Long-term debt is projected to decrease significantly to EUR 14.4 million in fiscal 2026.
The company faces low dilution and credit risk levels according to current risk flag assessments.
Net losses widened dramatically to EUR 15.4 million in fiscal 2025, reflecting severe profitability challenges.
Free cash flow deteriorated to negative EUR 15 million in fiscal 2025, indicating significant cash burn.
Operating and net margins rank in the bottom quartile compared to the broader pharmaceutical cohort median.
Revenue has declined at a 9.8% compound annual growth rate over the last four fiscal years.
The company carries a negative book value of EUR 11.8 million, signaling substantial accumulated losses.
In focus — financials by report
Revenue €7.7M, +62,0% YoY.
- ▍Revenue €7.7M, +62,0% YoY
Revenue €4.7M, −48,3% YoY; Operating income −48,2% YoY.
- ▍Revenue €4.7M, −48,3% YoY
- ▍Operating income −48,2% YoY
- ▍Net income −126,9% YoY
- ▍Free cash flow −139,6% YoY
- ▍Net margin -324.8%
Revenue €9.2M, −18,6% YoY; Operating income −4,4% YoY.
- ▍Revenue €9.2M, −18,6% YoY
- ▍Operating income −4,4% YoY
- ▍Net income −6,2% YoY
- ▍Free cash flow −4,9% YoY
- ▍Net margin -74.0%
Revenue €11.3M, −3,0% YoY; Operating income −18,6% YoY.
- ▍Revenue €11.3M, −3,0% YoY
- ▍Operating income −18,6% YoY
- ▍Net income −8,6% YoY
- ▍Free cash flow +4,3% YoY
- ▍Net margin -56.7%
Revenue €11.6M; Operating income -€4.1M.
- ▍Revenue €11.6M
- ▍Operating income -€4.1M
- ▍Net margin -50.7%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,48 |
| Revenue | —no estimate | —no estimate | 10,1M EUR |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Marinomed Biotech AG Market data — financials · 2026-05-28
- Marinomed Biotech AG Market data — analyst estimates · 2026-05-28